Daily BriefsECM

Daily Brief ECM: Hudco Oct 23 OFS – Momentum Has Been Strong and more

In today’s briefing:

  • Hudco Oct 23 OFS – Momentum Has Been Strong, and Appears to Be Well Flagged
  • Pre-IPO VISEN Pharmaceuticals – The Product Pipeline and the Key Risks
  • Cuscal IPO – Peer Comparison & Thoughts on Valuation


Hudco Oct 23 OFS – Momentum Has Been Strong, and Appears to Be Well Flagged

By Clarence Chu

  • The Government of India (GoI) is looking to raise up to US$130m from trimming its stake in Housing and Urban Development Corporation Limited (HUDCO IN)
  • The base deal includes a 3.5% stake sale, with an option to double it up to 7%. The selldown is targeted at meeting SEBI’s minimum public float requirements of 25%. 
  • At 7.5 days of three month ADV, the deal isn’t a very large one for the firm to digest.

Pre-IPO VISEN Pharmaceuticals – The Product Pipeline and the Key Risks

By Xinyao (Criss) Wang

  • VISEN’s candidates are potential Best-In-Class or represent novel technologies, but they need to obtain doctors/authorities’ recognition.The competition pattern in growth hormone market would continue to deteriorate with increasing new entrants. 
  • Once the growth hormone market is taken seriously by the regulatory authorities, the industry’s growth momentum would be challenged. The actual market space could be greatly reduced as a result.
  • In front of competitors with strong sales system, commercialization is a big challenge for VISEN. The Company has yet to prove this.VBP news on rhGH would weigh on market sentiment.

Cuscal IPO – Peer Comparison & Thoughts on Valuation

By Clarence Chu

  • Cuscal Limited (1229Z AU) is looking to raise US$234m in its upcoming Australia IPO.
  • Cuscal is an authorized deposit-taking institution (ADI) in Australia that primarily provides financial infrastructure and payment services in Australia.
  • In our previous note we looked at the company’s past performance, in this note we will undertake a peer comparison and share our thoughts on valuation.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars